Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KEYNOTE-937 adjuvant pembrolizumab in hepatocellular carcinoma after complete response
jRCT2080224710Phase 3Completed
- Sponsor
- Merck & Co.
- Start
- Jun 2019
- Modality
- Immune Checkpoint Inhibitors → Monoclonal Antibodies → Antibody-Based Therapeutics, Recombinant Proteins and Enzymes
01
Overview
Phase 3, randomised, double-blind trial in hepatocellular carcinoma (HCC) comparing Pembrolizumab with Placebo (2 arms). Primary endpoint: Recurrence-free survival. Started Jun 2019; status: completed.
02
Drugs
03
Conditions
hepatocellular carcinoma (HCC)
Beyond the preview
Go deeper on jRCT2080224710.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on jRCT2080224710.